Statistiche di base
| LEI | 5299007Y1X8RBDFT8C40 |
| CIK | 1426800 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Assembly Biosciences, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 11, 2025 |
COMMON STOCK PURCHASE WARRANT ASSEMBLY BIOSCIENCES, INC. EX-4.2 exhibit 4.2 COMMON STOCK PURCHASE WARRANT ASSEMBLY BIOSCIENCES, INC. Warrant Shares: [] Initial Exercise Date: August 11, 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after November |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 11, 2025 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-285970 Registration No. 333-289395 PROSPECTUS SUPPLEMENT (To prospectus dated April 1, 2025) 5,591,840 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,040,820 Shares of Common Stock Class A Warrants to Purchase up to 3,316,330 Shares of Common Stock Class B Warrants to Purchase up to 3,316,330 Shares of Co |
|
| August 11, 2025 |
EX-4.3 Exhibit 4.3 PRE-FUNDED WARRANT ASSEMBLY BIOSCIENCES, INC. Warrant Shares: [] Initial Exercise Date: August 11, 2025 THIS PRE-FUNDED WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial E |
|
| August 11, 2025 |
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings EX-99.1 Exhibit 99.1 Assembly Biosciences Announces Pricing of $175 Million in Equity Financings August 8, 2025 SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering (the |
|
| August 11, 2025 |
SUBJECT TO COMPLETION, DATED AUGUST 7, 2025 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| August 11, 2025 |
EX-10.1 exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 8, 2025, between Assembly Biosciences, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc. (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) |
|
| August 11, 2025 |
EX-4.4 exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| August 11, 2025 |
EX-1.1 Exhibit 1.1 Execution Version 5,591,840 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,040,820 Shares of Common Stock Class A Common Warrants to Purchase up to 3,316,330 Shares of Common Stock Class B Common Warrants to Purchase up to 3,316,330 Shares of Common Stock Assembly Biosciences, Inc. UNDERWRITING AGREEMENT August 8, 2025 GUGGENHEIM SECURITIES, LLC As Representative |
|
| August 11, 2025 |
EX-4.5 Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| August 11, 2025 |
EX-4.1 Exhibit exa COMMON STOCK PURCHASE WARRANT ASSEMBLY BIOSCIENCES, INC. Warrant Shares: [] Initial Exercise Date: August 11, 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 8, 2025 |
EX-99.1 Exhibit 99.1 Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes – 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort |
|
| August 7, 2025 |
As filed with the Securities and Exchange Commission on August 7, 2025 S-3MEF As filed with the Securities and Exchange Commission on August 7, 2025 Registration No. |
|
| August 7, 2025 |
Calculation of Filing Fee Tables S-3 ASSEMBLY BIOSCIENCES, INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCIENCES |
|
| August 6, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Assembly Biosciences, Inc. |
|
| August 6, 2025 |
Exhibit 99.2 Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus – Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – Fu |
|
| August 6, 2025 |
Exhibit 99.1 Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates – On track for proof-of-concept Phase 1b data this no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-5366 and ABI-1179 – – Positive topline data reported for Phase 1b study of ABI-4334, a next-ge |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 25, 2025 |
Exhibit 99.1 Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B – Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 logs IU/mL ov |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 9, 2025 |
Amendment No. 2 to Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan. Exhibit 10.2 AMENDMENT NO. 2 TO ASSEMBLY BIOSCIENCES, INC. AMENDED AND RESTATED 2018 STOCK INCENTIVE PLAN Assembly Biosciences, Inc., a Delaware corporation (the “Company”) adopted the Assembly Biosciences, Inc, Amended and Restated 2018 Stock Incentive Plan on May 29, 2024 (the “Plan”). Prior to this Amendment No. 2 to the Plan, assuming Amendment No. 1 is approved by the Company’s stockholders, |
|
| June 9, 2025 |
Amendment No. 1 to Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan. Exhibit 10.1 AMENDMENT NO. 1 TO ASSEMBLY BIOSCIENCES, INC. AMENDED AND RESTATED 2018 STOCK INCENTIVE PLAN Assembly Biosciences, Inc., a Delaware corporation (the “Company”) adopted the Assembly Biosciences, Inc, Amended and Restated 2018 Stock Incentive Plan on May 29, 2024 (the “Plan”). Prior to this Amendment No. 1 to the Plan, the number of shares of Common Stock, par value $0.001 per share, re |
|
| June 9, 2025 |
Exhibit 10.3 AMENDMENT NO. 1 TO ASSEMBLY BIOSCIENCES, INC. SECOND AMENDED AND RESTATED 2018 EMPLOYEE STOCK PURCHASE PLAN Assembly Biosciences, Inc., a Delaware corporation (the “Company”) adopted the Assembly Biosciences, Inc, Second Amended and Restated 2018 Employee Stock Purchase Plan on May 29, 2024 (the “ESPP”). Prior to this Amendment No. 1 to the ESPP, the number of shares of Common Stock, |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCIENCE |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2025 |
Exhibit 99.1 Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates – Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – – New data from multiple programs highlighted at ICAR, ESCMID and EASL 2025 – SOUTH SAN FRANC |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defin |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defin |
|
| March 28, 2025 |
Two Tower Place, 7th Floor, South San Francisco, CA 94080 CORRESP March 28, 2025 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 20, 2025 |
As filed with the Securities and Exchange Commission on March 20, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 20, 2025 |
Exhibit 99.1 Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights – Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – – Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and ABI-1179, long-acting helicase-primase inhibitor c |
|
| March 20, 2025 |
Specimen Common Stock Certificate Exhibit 4.1 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP 045396 20 7 SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF Assembly Biosciences, Inc. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly endo |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35005 ASSEMBLY BIOSCIENCES, INC. |
|
| March 20, 2025 |
EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Table Form S-3 (Form Type) Assembly Biosciences, Inc. |
|
| March 20, 2025 |
List of Subsidiaries of Assembly Biosciences, Inc. Exhibit 21.1 Subsidiaries of Assembly Biosciences, Inc. Subsidiaries State or Other Jurisdiction of Incorporation or Organization Assembly Pharmaceuticals, Inc. Delaware Assembly Biosciences Hong Kong Limited Hong Kong Assembly Biosciences Cayman Cayman Islands |
|
| March 20, 2025 |
Assembly Biosciences, Inc. Insider Trading Policy Exhibit 19.1 INSIDER TRADING POLICY INTRODUCTION While performing their duties, officers, directors, employees, consultants and contractors (each a “Covered Person”) of Assembly Biosciences, Inc. (“Assembly Bio”) may receive information regarding Assembly Bio (and possibly other public companies) that is not generally available to the public. U.S. federal securities laws contain provisions designe |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 20, 2025 |
Exhibit 99.1 Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes – ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose – |
|
| January 3, 2025 |
Exhibit 10.1 FIRST AMENDMENT TO SUBLEASE THIS FIRST AMENDMENT TO SUBLEASE (this “Amendment”) is made as of December 30, 2024 by and between ARSENAL BIOSCIENCES, INC., a Delaware corporation (“Sublessor”) and ASSEMBLY BIOSCIENCES, INC., a Delaware corporation (“Sublessee”), with reference to the following facts and objectives: RECITALS A. Sublessor, as tenant, and AP3-SF3 CT NORTH, LLC, as predeces |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 26, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 26, 2024 |
Exhibit 99.1 Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B – ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity with a mean reductio |
|
| December 23, 2024 |
Exhibit 99 The name and present principal occupation of each of the executive officers and directors of Gilead Sciences, Inc. |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 19, 2024 |
Exhibit 10.1 CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. First AMENDMENT TO OPTION, LICENSE AND COLLABORATION AGREEMENT This First Amendment to Option, License and Collaboration Agreement (this “First Amendment”), date |
|
| December 13, 2024 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ASSEMBLY BIOSCIENCES, INC. (as amended through December 12, 2024) 1 Article I OFFICES 1.1 Registered Office. The registered office of ASSEMBLY BIOSCIENCES, INC. (the “Corporation”), in the State of Delaware is 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808, and its registered agent at such address is Corporation Service Company. 1.2 |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2024 |
ASMB / Assembly Biosciences, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-asmb093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ASSEMBLY BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 045396207 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| November 7, 2024 |
Open Market Sale Agreement by and between Assembly Biosciences, Inc. and Jefferies LLC. Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM November 7, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Assembly Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s com |
|
| November 7, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 7, 2024 |
Up to $75,000,000 of Shares of Common Stock Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-270760 PROSPECTUS SUPPLEMENT (To prospectus dated April 14, 2023) Up to $75,000,000 of Shares of Common Stock Common Stock We have entered into an Open Market Sale AgreementSM (the “Sale Agreement”) with Jefferies LLC (“Jefferies”) relating to shares of our common stock, par value $0.001 per share, offered by this prospe |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCI |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 7, 2024 |
Exhibit 99.1 Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates • Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral dosing • First participants dosed in Phase 1b trial evaluating ABI-5366 in individuals with recurrent |
|
| September 23, 2024 |
Exhibit 99.1 Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 – ABI-5366 was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days – – Half-life of approximately 20 days supports once-weekly or once-monthly oral dosing; both dosing schedules will be explored in t |
|
| September 23, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 8, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Assembly Biosciences, Inc. |
|
| August 8, 2024 |
As filed with the Securities and Exchange Commission on August 8, 2024 As filed with the Securities and Exchange Commission on August 8, 2024 Registration No. |
|
| August 8, 2024 |
Exhibit 99.1 Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates • Dosing initiated in healthy participants in Phase 1a/b trial for ABI-5366 targeting recurrent genital herpes, with interim Phase 1a first-in-human data expected in Q3 2024 and interim Phase 1b data in participants with recurrent genital herpes expected in first half of 2025 • Dosing initiated in Ph |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCIENCES |
|
| June 24, 2024 |
ASMB / Assembly Biosciences, Inc. / Schornstein Alexander - SCHEDULE 13D/A Activist Investment SC 13D/A 1 schornstein13da.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Amendment No. 3 ASSEMBLY BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 0453961080 (CUSIP Number) Alexander Schornstein Kaiser-Friedrich-Allee 2, 52074 Aachen Germany 0049151423 |
|
| June 20, 2024 |
ASMB / Assembly Biosciences, Inc. / GILEAD SCIENCES INC Activist Investment SC 13D/A 1 s13da061724-assemblybio.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) ASSEMBLY BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 0453961080 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 650-574-3000 |
|
| June 18, 2024 |
Exhibit 10.3 ASSEMBLY BIOSCIENCES, INC. AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENT This Amendment No. 1 to Common Stock Purchase Agreement (this “Amendment”) is dated as of June 17, 2024, by and between Assembly Biosciences, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc., a Delaware corporation (“Gilead,” and together with the Company, the “Parties”). All capitaliz |
|
| June 18, 2024 |
Exhibit 10.4 ASSEMBLY BIOSCIENCES, INC. AMENDMENT NO. 1 TO INVESTOR RIGHTS AGREEMENT This Amendment No. 1 to Investor Rights Agreement (this “Amendment”) is dated as of June 17, 2024, by and between Assembly Biosciences, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc., a Delaware corporation (“Gilead,” and together with the Company, the “Parties”). All capitalized terms not |
|
| June 18, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 16, 2024, between Assembly Biosciences, Inc., a Delaware corporation (the “Company”), and Armistice Capital LLC (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration |
|
| June 18, 2024 |
Exhibit 99.1 Assembly Biosciences Announces $12.6 Million in Equity Financings — Funding supports advancement of antiviral portfolio, including four candidates in clinical development, and extends cash runway into Q1 2026 — — Anticipated near term interim data read outs include ABI-5366 Phase 1a in 3Q24 and Phase 1b in 1H25, and ABI-4334 Phase 1b by end of 2024 — SOUTH SAN FRANCISCO, Calif., June |
|
| June 18, 2024 |
634,500 Shares of Common Stock Warrants to Purchase 634,500 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-270760 PROSPECTUS SUPPLEMENT (To prospectus dated April 14, 2023) 634,500 Shares of Common Stock Warrants to Purchase 634,500 Shares of Common Stock We are offering 634,500 shares of our common stock, par value $0.001 per share, and accompanying warrants to purchase up to 634,500 shares of our common stock, in a registered dir |
|
| June 18, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 18, 2024 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 17, 2024, between Assembly Biosciences, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc. (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Se |
|
| June 18, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 18, 2024 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT ASSEMBLY BIOSCIENCES, INC. Warrant Shares: 634,500 Initial Exercise Date: June 16, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an |
|
| June 3, 2024 |
Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan. Exhibit 10.1 ASSEMBLY BIOSCIENCES, INC. amended and restated 2018 STOCK INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. 2. Definitions. The following definitions shall apply as used herein and in the |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 3, 2024 |
Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan. Exhibit 10.2 SECOND AMENDED AND RESTATED 2018 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan (“the Plan”) is to provide eligible employees of Assembly Biosciences, Inc. (the “Company”) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0.001 per share |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCIENCE |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2024 |
Exhibit 99.1 Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights • Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on track to initiate by mid-2024 • ABI-5366 interim Phase 1a first-in-human data expected in Q3 2024 and |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defin |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defin |
|
| March 28, 2024 |
Exhibit 99.1 Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights • Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end • Clinical development timelines accelerated for ABI-5366; now anticipating interim data from Phase 1a available in 3Q2024, initiation of Phase 1b in individuals |
|
| March 28, 2024 |
Sixth Amended and Restated Certificate of Incorporation dated May 25, 2022. Exhibit 3.1 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ASSEMBLY BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Assembly Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), certifies that: A. The name of the cor |
|
| March 28, 2024 |
List of Subsidiaries of Assembly Biosciences, Inc. Exhibit 21.1 Subsidiaries of Assembly Biosciences, Inc. Subsidiaries State or Other Jurisdiction of Incorporation or Organization Assembly Pharmaceuticals, Inc. Delaware Assembly Biotechnology Development (Shanghai) Co, Ltd. China Assembly Biosciences Hong Kong Limited Hong Kong Assembly Biosciences Cayman Cayman Islands |
|
| March 28, 2024 |
Exhibit 97.1 CLAWBACK POLICY The Board of Directors (the “Board”) of Assembly Biosciences, Inc. (the “Company”) believes that it is appropriate for the Company to adopt this Clawback Policy (the “Policy”) to be applied to the Executive Officers of the Company and adopts this Policy to be effective as of the Effective Date. 1. Definitions For purposes of this Policy, the following definitions shall |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 28, 2024 |
Exhibit 10.11 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of November 8, 2023 (the “Execution Date”) with an effective date as of the first date of employment which is anticipated to be November 8, 2023 (the “Effective Date“), by and between Assembly Biosciences, Inc., a Delaware corporation with principal executive offices at 331 Oyster Point Blvd., South |
|
| March 28, 2024 |
Exhibit 10.12 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of February 1, 2022 (the “Execution Date”) with an effective date February 10, 2022 (the “Effective Date“), by and between Assembly Biosciences, Inc., a Delaware corporation with principal executive offices at 331 Oyster Point Blvd., Fourth Floor, South San Francisco, CA 94080 (the “Company”), and Ni |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35005 ASSEMBLY BIOSCIENCES, INC. |
|
| March 28, 2024 |
Exhibit 4.2 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Assembly Biosciences, Inc. (Assembly, the Company, we, us and our) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. DESCRIPTION OF CAPITAL STOCK The following description of our capital |
|
| March 15, 2024 |
Assembly Biosciences, Inc. 2024 Corporate Bonus Plan. Exhibit 10.1 ASSEMBLY BIOSCIENCES, INC. 2024 CORPORATE BONUS PLAN Overview The 2024 Corporate Bonus Plan (the “Plan”) of Assembly Biosciences, Inc. (the “Company”) is, upon approval by the Compensation Committee (the “Committee”) of the Board of Directors of the Company (the “Board”), effective as of January 1, 2024 (the “Effective Date”). The Plan is designed to motivate, retain, attract and rewa |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 13, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ASSEMBLY BIOSCIENCES, INC. ASSEMBLY BIOSCIENCES, INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is Assembly Biosciences, In |
|
| February 13, 2024 |
Exhibit 99.1 Assembly Biosciences Announces Effective Date of Reverse Stock Split – Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Calif., Feb. 8, 2024 - Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that it e |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 21, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 11, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2023 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 22, 2023 |
ASMB / Assembly Biosciences Inc / Schornstein Alexander - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Amendment No. 2 ASSEMBLY BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 0453961080 (CUSIP Number) Alexander Schornstein Kaiser-Friedrich-Allee 2, 52074 Aachen Germany 004915142314669 (Name, Address and Telephone Number of P |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 8, 2023 |
EXHIBIT 10.1 SUBLEASE THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of August 4, 2023, and is made by and between ARSENAL BIOSCIENCES, INC., a Delaware corporation (“Sublessor”), and ASSEMBLY BIOSCIENCES, INC., a Delaware corporation (“Sublessee”). Sublessor and Sublessee hereby agree as follows: 1. Recitals: This Sublease is made with reference to the fact that AP3-SF3 CT NOR |
|
| November 8, 2023 |
Exhibit 99.1 Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates - Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond - Now anticipate four development candidates from expanded pipeline in clinical development by the end of 2024 - Named Anuj Gaggar, MD, PhD, as chief medical officer - $100 millio |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCI |
|
| November 3, 2023 |
ASMB / Assembly Biosciences Inc / Schornstein Alexander - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Amendment No. 1 ASSEMBLY BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 0453961080 (CUSIP Number) Alexander Schornstein Kaiser-Friedrich-Allee 2, 52074 Aachen Germany 004915142314669 (Name, Address and Telephone Number of P |
|
| October 25, 2023 |
ASMB / Assembly Biosciences Inc / GILEAD SCIENCES INC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ASSEMBLY BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 0453961080 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 650-574-3000 (Name, Address and Telephone Number of |
|
| October 17, 2023 |
EX-10.1 Exhibit 10.1 CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. Confidential OPTION, LICENSE AND COLLABORATION AGREEMENT by and between Assembly Biosciences, Inc. and Gilead Sciences, Inc. dated as of October 15, 2023 |
|
| October 17, 2023 |
EX-10.3 Exhibit 10.3 CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. ASSEMBLY BIOSCIENCES, INC. INVESTOR RIGHTS AGREEMENT This Investor Rights Agreement (this “Agreement”) is made as of October 15, 2023 (the “Effective Dat |
|
| October 17, 2023 |
EX-10.2 Exhibit 10.2 CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. ASSEMBLY BIOSCIENCES, INC. COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this “Agreement”) is dated as of October 15, 2023, by an |
|
| October 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2023 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 29, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 9, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Assembly Biosciences, Inc. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCIENCES |
|
| August 9, 2023 |
Exhibit 99.1 Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates - Herpesvirus candidate ABI-5366 anticipated to enter clinic in first half of 2024 - New data for several pipeline programs presented at IHW and EASL 2023 - Additional development candidate nomination expected in 2023 SOUTH SAN FRANCISCO, Calif., August 9, 2023 (GLOBE NEWSWIRE) - Assembly Biosciences |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 9, 2023 |
As filed with the Securities and Exchange Commission on August 9, 2023 As filed with the Securities and Exchange Commission on August 9, 2023 Registration No. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 30, 2023 |
Amendment No. 6 to Assembly Biosciences, Inc. 2018 Stock Incentive Plan. Exhibit 10.1 AMENDMENT NO. 6 TO ASSEMBLY BIOSCIENCES, INC. 2018 STOCK INCENTIVE PLAN Assembly Biosciences, Inc., a Delaware corporation (the “Company”) adopted the 2018 Stock Incentive Plan on May 30, 2018, which was amended by Amendment No. 1 to Assembly Biosciences, Inc. 2018 Stock Incentive Plan effective as of May 17, 2019, by Omnibus Amendment to Assembly Biosciences, Inc. Stock Plans effecti |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCIENCE |
|
| May 4, 2023 |
Exhibit 99.1 Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights - Herpesvirus candidate ABI-5366 progressing towards IND and planned to enter the clinic in the first half of 2024 - Additional development candidate nomination anticipated in 2023 - Multiple abstracts accepted for presentation at EASL 2023 in June SOUTH SAN FRANCISCO, Calif., May 4, 2023 (GLOBE NE |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 18, 2023 |
Exhibit 99.1 Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update • Phase 1a clinical data for remaining 200 mg multiple dose cohort for ABI-4334 continue to demonstrate encouraging clinical profile with strong projected activity against both viral replication an |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defin |
|
| April 12, 2023 |
Definitive Proxy Statement for the 2023 Annual Meeting of Stockholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defin |
|
| April 12, 2023 |
331 Oyster Point Blvd., 4th Flr., South San Francisco, CA 94080 April 12, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defin |
|
| March 22, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Assembly Biosciences, Inc. |
|
| March 22, 2023 |
Exhibit 10.7 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of December 12, 2022 (the “Execution Date”), with an effective date as of January 1, 2023 (the “Effective Date”), by and between Assembly Biosciences, Inc., a Delaware corporation with principal executive offices at 331 Oyster Point Blvd., Fourth Floor, South San Francisco, CA 940 |
|
| March 22, 2023 |
Exhibit 4.2 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Assembly Biosciences, Inc. (Assembly, the Company, we, us and our) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. DESCRIPTION OF CAPITAL STOCK The following description of our capital |
|
| March 22, 2023 |
Form of Notice of Stock Option Grant and Stock Option Agreement under the 2018 Stock Incentive Plan. Exhibit 10.22 ASSEMBLY BIOSCIENCES, INC. 2018 Stock Incentive Plan NOTICE OF STOCK OPTION GRANT Grant Number [Name] [Address] You have been granted an option to purchase Common Stock of Assembly Biosciences, Inc. (the "Company"), as follows: Date of Grant [●] Vesting Commencement Date [●] Exercise Price per Share $[●] Total Number of Shares Granted [●] Total Exercise Price $[●] Type of Option: Inc |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35005 ASSEMBLY BIOSCIENCES, INC. |
|
| March 22, 2023 |
Exhibit 10.12 ASSEMBLY BIOSCIENCES, INC. Amended and Restated 2014 Stock Incentive Plan NOTICE OF STOCK OPTION GRANT Grant Number [Name] [Address] You have been granted an option to purchase Common Stock of Assembly Biosciences, Inc. (the "Company"), as follows: Date of Grant [●] Vesting Commencement Date [●] Exercise Price per Share $[●] Total Number of Shares Granted [●] Total Exercise Price $[● |
|
| March 22, 2023 |
List of Subsidiaries of Assembly Biosciences, Inc. Exhibit 21.1 Subsidiaries of Assembly Biosciences, Inc. Subsidiaries State or Other Jurisdiction of Incorporation or Organization Assembly Pharmaceuticals, Inc. Delaware Assembly Biotechnology Development (Shanghai) Co, Ltd. China Assembly Biosciences Hong Kong Limited Hong Kong Assembly Biosciences Cayman Cayman Islands |
|
| March 22, 2023 |
As filed with the Securities and Exchange Commission on March 22, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on March 22, 2023 Registration No. |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 22, 2023 |
Exhibit 99.1 Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights • Prioritization of core inhibitor candidate ABI-4334 and pausing of core inhibitor candidate ABI-H3733 based on data to date from ongoing clinical Phase 1 studies of both candidates and chronic toxicology observation for ABI-H3733 • Pha |
|
| February 15, 2023 |
Exhibit 99.1 Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes −ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., February 15, |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 14, 2023 |
ASMB / Assembly Biosciences Inc / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-asmb123122a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ASSEMBLY BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 045396108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| December 19, 2022 |
Exhibit 99.1 Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334 In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction of 3.1 logs in |
|
| December 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 12, 2022 |
Amended and Restated Bylaws as amended through December 7, 2022. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ASSEMBLY BIOSCIENCES, INC. (as amended through December 7, 2022) Article I OFFICES 1.1 Registered Office. The registered office of ASSEMBLY BIOSCIENCES, INC. (the “Corporation”), in the State of Delaware is 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808, and its registered agent at such address is Corporation Service Company. 1.2 Pr |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCI |
|
| November 8, 2022 |
Exhibit 99.1 Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance SOUTH SAN FRANCISCO, Calif., November 8, 2022 (GLOBE NEWSWIRE) - Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage |
|
| October 5, 2022 |
Exhibit 99.1 Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the board SOUTH SAN FRANCISCO, Calif., October 5, 2022 (GLOBE NEWSWIRE) ? Assembly Biosciences, Inc. (Nasdaq: ASMB), |
|
| October 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2022 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCIENCES |
|
| August 9, 2022 |
As filed with the Securities and Exchange Commission on August 9, 2022 As filed with the Securities and Exchange Commission on August 9, 2022 Registration No. |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 9, 2022 |
Exhibit 99.1 Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., August 9, 2022 (GLOBE NEWSWIRE) - Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced financial results and rec |
|
| August 9, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) ASSEMBLY BIOSCIENCES, INC. |
|
| July 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 20, 2022 |
Assembly Biosciences Announces Program Reprioritization and Organizational Update Exhibit 99.1 Assembly Biosciences Announces Program Reprioritization and Organizational Update - Discontinues clinical development of vebicorvir, Assembly Bio?s first-generation core inhibitor, based on interim efficacy data from ongoing combination clinical studies - Advancing next-generation, significantly more potent core inhibitors, ABI-H3733 and ABI-4334, in clinical studies - Prioritizes res |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 27, 2022 |
Amendment No. 5 to Assembly Biosciences, Inc. 2018 Stock Incentive Plan. Exhibit 10.1 AMENDMENT NO. 5 TO ASSEMBLY BIOSCIENCES, INC. 2018 STOCK INCENTIVE PLAN Assembly Biosciences, Inc., a Delaware corporation (the ?Company?) adopted the 2018 Stock Incentive Plan on May 30, 2018, which was amended by Amendment No. 1 to Assembly Biosciences, Inc. 2018 Stock Incentive Plan effective as of May 17, 2019, by Omnibus Amendment to Assembly Biosciences, Inc. Stock Plans effecti |
|
| May 27, 2022 |
Exhibit 3.1 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ASSEMBLY BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Assembly Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?DGCL?), certifies that: A. The name of the cor |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2022 |
Exhibit 99.1 Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) - Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCIENCE |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 12, 2022 |
DEF 14A 1 asmb-def14a20220525.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defin |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defin |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35005 ASSEMBLY BIOSCIENCES, INC. |
|
| March 11, 2022 |
Exhibit 10.27 STOCK APPRECIATION RIGHT award AGREEMENT for non-u.s. Grantees UNDER THE Assembly Biosciences, INc. 2018 STOCK INCENTIVE PLAN Name of Grantee: No. of SARs: [?] Exercise Price per Share: [?] Grant Date: [?] Expiration Date: [?] Post-Termination Exercise Period Except as provided in Section 2, Vested SARs may be exercised for up to 90 days after termination of Continuous Service. Pursu |
|
| March 11, 2022 |
List of Subsidiaries of Assembly Biosciences, Inc. Exhibit 21.1 Subsidiaries of Assembly Biosciences, Inc. Subsidiaries State or Other Jurisdiction of Incorporation or Organization Assembly Pharmaceuticals, Inc. Delaware Assembly Biotechnology Development (Shanghai) Co, Ltd. China Assembly Biosciences Hong Kong Limited Hong Kong Assembly Biosciences Cayman Cayman Islands |
|
| March 11, 2022 |
Exhibit 4.2 DESCRIPTION OF THE COMPANY?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Assembly Biosciences, Inc. (Assembly, the Company, we, us and our) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. DESCRIPTION OF CAPITAL STOCK The following description of our capital |
|
| March 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 10, 2022 |
Exhibit 99.1 Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) - Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent h |
|
| February 15, 2022 |
Exhibit A AGREEMENT The undersigned agree that this Amendment No. 1 to Schedule 13G dated February 14, 2022 relating to the Common Stock, par value $0.001 per share, of Assembly Biosciences, Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd |
|
| February 15, 2022 |
ASMB / Assembly Biosciences Inc / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
ASMB / Assembly Biosciences Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ASSEMBLY BIOSCIENCES INC (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 045396108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 10, 2022 |
ASMB / Assembly Biosciences Inc / Satter Muneer A - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Assembly Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 045396108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the Appropriate Box to Designat |
|
| February 9, 2022 |
ASMB / Assembly Biosciences Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Assembly Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 045396108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 4, 2022 |
Assembly Biosciences, Inc. 2022 Corporate Bonus Plan. Exhibit 10.1 ASSEMBLY BIOSCIENCES, INC. 2022 CORPORATE BONUS PLAN Overview The 2022 Corporate Bonus Plan (the ?Plan?) of Assembly Biosciences, Inc. (the ?Company?) is, upon approval by the Compensation Committee (the ?Committee?) of the Board of Directors of the Company (the ?Board?), effective as of January 1, 2021 (the ?Effective Date?). The Plan is designed to motivate, retain, attract and rewa |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2022 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 4, 2022 |
Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones Exhibit 99.1 Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones SOUTH SAN FRANCISCO, Calif., Jan. 4, 2022 (GLOBE NEWSWIRE) - Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today outlined anticipated progress and milestones for its development |
|
| January 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2022 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 4, 2021 |
Employment Agreement, dated July 30, 2021, between Assembly Biosciences, Inc. and Michael P. Samar. Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?), is entered into as of July 30, 2021 (the ?Execution Date?) with an effective date of August 1, 2021 (the ?Effective Date?), by and between Assembly Biosciences, Inc., a Delaware corporation with principal executive offices at 331 Oyster Point Blvd., Fourth Floor, South San Francisco, CA 94080 (the ?Company?), and Michae |
|
| November 4, 2021 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?), is entered into as of July 30, 2021 (the ?Execution Date?) with an effective date as of August 1, 2021 (the ?Effective Date?), by and between Assembly Biosciences, Inc., a Delaware corporation with principal executive offices at 331 Oyster Point Blvd., Fourth Floor, South San Francisco, CA 94080 (th |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCI |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 4, 2021 |
Exhibit 99.1 Assembly Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., Nov. 4, 2021 (GLOBE NEWSWIRE) - Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the third quarter ended Sep |
|
| October 12, 2021 |
ASMB / Assembly Biosciences Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 1, 2021 |
Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158 Exhibit 99.1 Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158 -Decision follows observation of elevated alanine transaminase (ALT) levels in Phase 2 study -Company will focus on advancing ongoing triple combination studies and earlier pipeline candidates SOUTH SAN FRANCISCO, Calif., September 1, 2021 (GLOBE NEWSWIRE) - Assembly Biosciences, Inc. (Nasdaq: ASMB), a cl |
|
| September 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2021 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 5, 2021 |
Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights Exhibit 99.1 Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, CA, August 5, 2021 - Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the second quarter ended June 30, 2021. ?With |
|
| August 5, 2021 |
As filed with the Securities and Exchange Commission on August 5, 2021 As filed with the Securities and Exchange Commission on August 5, 2021 Registration No. |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCIENCES |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2021 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2021 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 20, 2021 |
Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors Exhibit 99.1 Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors - Esteemed academic and industry virologist discovered hepatitis C virus (HCV); brings 40+ years of scientific and drug development experience - SOUTH SAN FRANCISCO, CA, July 20, 2021 - Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeu |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 25, 2021 |
Amended and Restated Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan. Exhibit 10.2 AMENDED AND RESTATED 2018 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan (?the Plan?) is to provide eligible employees of Assembly Biosciences, Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, par value $0.01 per share (the ?C |
|
| May 25, 2021 |
Amendment No. 4 to Assembly Biosciences, Inc. 2018 Stock Incentive Plan. Exhibit 10.1 AMENDMENT NO. 4 TO ASSEMBLY BIOSCIENCES, INC. 2018 STOCK INCENTIVE PLAN Assembly Biosciences, Inc., a Delaware corporation (the ?Company?) adopted the 2018 Stock Incentive Plan on May 30, 2018, which was amended by Amendment No. 1 to Assembly Biosciences, Inc. 2018 Stock Incentive Plan effective as of May 17, 2019, by Omnibus Amendment to Assembly Biosciences, Inc. Stock Plans effecti |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCIENCE |
|
| May 6, 2021 |
Assembly Biosciences Reports First Quarter 2021 Financial Results and Recent Updates Exhibit 99.1 Assembly Biosciences Reports First Quarter 2021 Financial Results and Recent Updates SOUTH SAN FRANCISCO, CA, May 6, 2021 - Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent updates for the first quarter ended March 31, 2021. ?In the first q |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definit |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definit |
|
| February 26, 2021 |
Exhibit 99.1 Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus - Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care Nrtl therapy SOUTH SAN FRANCISCO, Calif., and WARMINSTER, Pa. - Feb. 26, 2021 (GLOBE NEWSWIRE |
|
| February 26, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2021 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 25, 2021 |
Exhibit 99.2 Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection - Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel targets - Extends cash runway into 2023 - Company to host |
|
| February 25, 2021 |
EX-99.1 2 asmb-ex99115.htm EX-99.1 Exhibit 99.1 Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, CA, February 25, 2021 - Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlight |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 25, 2021 |
EX-10.12 4 asmb-ex101216.htm EX-10.12 Exhibit 10.12 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of May 1, 2020 (the “Execution Date”) with an effective date as of the first date of employment which is anticipated to be May 27, 2020 (the “Effective Date“), by and between Assembly Biosciences, Inc., a Delaware corporation with principal executive offices at 3 |
|
| February 25, 2021 |
List of Subsidiaries of Assembly Biosciences, Inc. EX-21.1 5 asmb-ex2118.htm EX-21.1 Exhibit 21.1 Subsidiaries of Assembly Biosciences, Inc. Subsidiaries State or Other Jurisdiction of Incorporation or Organization Assembly Pharmaceuticals, Inc. Delaware Assembly Biosciences Ireland Limited* Ireland ASMB Microbiome China Holdco Limited* Ireland ASMB HBV China Holdco Limited* Ireland Assembly Biotechnology Development (Shanghai) Co, Ltd. China Asse |
|
| February 25, 2021 |
Exhibit 4.3 DESCRIPTION OF THE COMPANY?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2020, Assembly Biosciences, Inc. (Assembly, the Company, we, us and our) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. DESCRIPTION OF CAPITAL STOCK The following de |
|
| February 25, 2021 |
EX-10.11 3 asmb-ex101169.htm EX-10.11 Exhibit 10.11 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of March 23, 2020 (the “Execution Date”) with an effective date as of the first date of employment which is anticipated to be March 26, 2020 (the “Effective Date”), by and between Assembly Biosciences, Inc., a Delaware corporation with principal executive offices |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35005 ASSEMBLY BIOSCIENCES, INC. |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ASSEMBLY BIOSCIENCES INC (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 045396108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 17, 2021 |
Assembly Biosciences, Inc. 2021 Corporate Bonus Plan. EX-10.1 2 asmb-ex1016.htm EX-10.1 Exhibit 10.1 ASSEMBLY BIOSCIENCES, INC. 2021 CORPORATE BONUS PLAN Overview The 2021 Corporate Bonus Plan (the “Plan”) of Assembly Biosciences, Inc. (the “Company”) is, upon approval by the Compensation Committee (the “Committee”) of the Board of Directors of the Company (the “Board”), effective as of January 1, 2021 (the “Effective Date”). The Plan is designed to |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2021 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 16, 2021 |
SC 13G 1 asmb21621.htm CONSONANCE CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ASSEMBLY BIOSCIENCES INC (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 045396108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ASSEMBLY BIOSCIENCES INC (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 045396108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Assembly Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 045396108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Assembly Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 045396108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| February 9, 2021 |
By signing below, Prudential Financial, Inc. certifies that, to the best of its 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 27, 2021 |
Amended and Restated Bylaws as amended through January 22, 2021. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ASSEMBLY BIOSCIENCES, INC. (as amended through January 22, 2021) Article I OFFICES 1.1Registered Office. The registered office of ASSEMBLY BIOSCIENCES, INC. (the “Corporation”), in the State of Delaware is 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808, and its registered agent at such address is Corporation Service Company. 1.2Prin |
|
| January 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 12, 2021 |
CORRESP 1 filename1.htm January 12, 2021 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re:Assembly Biosciences, Inc. Form 10-K for the Year Ended December 31, 2019 Filed March 4, 2020 File No. 001-35005 Ladies and Gentlemen: Set forth below is Assembly Biosciences, Inc.’s (the “Company,” “we” or “our”) response to the comment |
|
| January 4, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Assembly Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 045396108 (CUSIP Number) December 22, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| December 8, 2020 |
Exhibit 99.1 Assembly Biosciences to Wind-Down Microbiome Program Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio SOUTH SAN FRANCISCO, Calif., December 8, 2020 (GLOBE NEWSWIRE) - Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that it |
|
| December 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2020 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 17, 2020 |
Exhibit 99.1 Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators SOUTH SAN FRANCISCO, Calif., November 16, 2020 (GLOBE NEWSWIRE) - Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-year collaboration and option agreement fo |
|
| November 17, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Assembly Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35005 20-8729264 (State or other jurisdiction of incorporation) (Commis |
|
| November 5, 2020 |
Exhibit 10.2 [* * *] Portions of this exhibit that are both not material and would likely cause competitive harm to the registrant if publicly disclosed have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. IURTC Agreement No. 2020-0121 AMENDMENT #2 TO EXCLUSIVE LICENSE AGREEMENT This Amendment #2 to Exclusive License Agreement (this “Amendment #2”) is entered into and effective as |
|
| November 5, 2020 |
EX-10.1 2 asmb-ex10129.htm EX-10.1 Exhibit 10.1 [* * *] Portions of this exhibit that are both not material and would likely cause competitive harm to the registrant if publicly disclosed have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. AMENDMENT #1 TO EXCLUSIVE LICENSE AGREEMENT This Amendment #1 to Exclusive License Agreement (“Amendment #1”) is entered into as of February 28 |
|
| November 5, 2020 |
Assembly Biosciences Reports Third Quarter 2020 Financial Results and Business Update EX-99.1 2 asmb-ex99128.htm EX-99.1 Exhibit 99.1 Assembly Biosciences Reports Third Quarter 2020 Financial Results and Business Update SOUTH SAN FRANCISCO, CA, November 5, 2020 - Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial r |
|
| November 5, 2020 |
Exhibit 99.2 Assembly Bio Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection - HBV field’s first core inhibitor combination study to assess off-treatment response has not achieved a meaningful rate of sustained virologic response - - Vebicorvir Phase 3 registrational program remains on track to initiate in H1 2021 for chronic s |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. Commission file number: 001-35005 ASSEMBLY BIOSCI |
|
| November 5, 2020 |
EX-10.3 4 asmb-ex103251.htm EX-10.3 Exhibit 10.3 [* * *] Portions of this exhibit that are both not material and would likely cause competitive harm to the registrant if publicly disclosed have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. COLLABORATION AGREEMENT This Collaboration Agreement (this “Agreement”) is made as of July 17, 2020 (the “Effective Date”), by and between Ass |
|
| October 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2020 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 21, 2020 |
Assembly Biosciences Appoints Gina Consylman to Board of Directors Exhibit 99.1 Assembly Biosciences Appoints Gina Consylman to Board of Directors SOUTH SAN FRANCISCO, Calif., October 20, 2020 (GLOBE NEWSWIRE) - Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Gina Consylman to its bo |
|
| September 3, 2020 |
CORRESP September 3, 2020 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
